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Abstract: BACKGROUND Loss of response is frequently encountered in patients with inflammatory
bowel disease (IBD) treated with antitumor necrosis factor (TNF) agents. Therapeutic drug monitoring
(TDM) and antidrug antibody measurement are increasingly used in this setting. METHODS To establish
a consensus on the use of TDM in the context of loss of response to anti-TNFs, we performed a vote
using a Delphi-style process followed by an expert panel discussion among 8 IBD specialists practicing in
Switzerland, Europe. Statements were rated on an even Likert-scale ranging from 1 (strong disagreement)
to 4 (strong agreement), based on expert opinion and the available literature. RESULTS The experts
agreed on the following statements: (i) loss of response is associated with inadequate drug levels in
both Crohn’s disease and ulcerative colitis; (ii) best timepoint for measuring drug levels is prior to the
next application (= trough levels) with different thresholds for anti-TNF agents (infliximab 5 ฀g/mL,
adalimumab 8 ฀g/mL, certolizumab pegol 10 ฀g/mL); (iii) antidrug antibodies are predictive for loss of
response; and (iv) antidrug-antibody titers and drug trough levels are key determinants in the treatment
algorithm. Data about non-anti-TNF biologics were considered too limited to propose recommendations.
CONCLUSION A Delphi-style consensus among 8 IBD experts shows that TDM and measurement of
antidrug-antibody titers are useful in the context of loss of response to anti-TNF. Optimal cutoff levels
depend on the type of anti-TNF. These values are critical in the decision making process. More studies
are needed to address the value of such measurements for non-anti-TNF biologics.
DOI: https://doi.org/10.1159/000501930
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Abstract
Background: Loss of response is frequently encountered in 
patients with inflammatory bowel disease (IBD) treated with 
antitumor necrosis factor (TNF) agents. Therapeutic drug 
monitoring (TDM) and antidrug antibody measurement are 
increasingly used in this setting. Methods: To establish a 
consensus on the use of TDM in the context of loss of re-
sponse to anti-TNFs, we performed a vote using a Delphi-
style process followed by an expert panel discussion among 
8 IBD specialists practicing in Switzerland, Europe. State-
ments were rated on an even Likert-scale ranging from 1 
(strong disagreement) to 4 (strong agreement), based on ex-
pert opinion and the available literature. Results: The ex-
perts agreed on the following statements: (i) loss of response 
is associated with inadequate drug levels in both Crohn’s dis-
ease and ulcerative colitis; (ii) best timepoint for measuring 
drug levels is prior to the next application (= trough levels) 
with different thresholds for anti-TNF agents (infliximab 
5 μg/mL, adalimumab 8 μg/mL, certolizumab pegol 10 μg/
mL); (iii) antidrug antibodies are predictive for loss of re-
sponse; and (iv) antidrug-antibody titers and drug trough 
levels are key determinants in the treatment algorithm. Data 
about non-anti-TNF biologics were considered too limited to 









































































propose recommendations. Conclusion: A Delphi-style con-
sensus among 8 IBD experts shows that TDM and measure-
ment of antidrug-antibody titers are useful in the context of 
loss of response to anti-TNF. Optimal cutoff levels depend on 
the type of anti-TNF. These values are critical in the decision 
making process. More studies are needed to address the val-
ue of such measurements for non-anti-TNF biologics.
© 2019 S. Karger AG, Basel
Introduction
Inflammatory bowel disease (IBD) with its 2 subtypes 
Crohn’s disease (CD) and ulcerative colitis (UC) is a 
chronic inflammatory disorder of the gastrointestinal 
tract [1]. Given a complex and yet only partially under-
stood etiopathogenesis, IBD is considered an incurable, 
but treatable disease [2, 3]. The introduction of antitumor 
necrosis factor (TNF) with considerable higher efficacy 
than conventional immunomodulatory drugs has dra-
matically changed the therapeutic management of IBD. 
However, loss of response is encountered in up to 46% of 
IBD patients treated with anti-TNF [4, 5]. Loss of re-
sponse implies a previous initial response to treatment, 
which is lost over time, and has to be differentiated from 
primary nonresponse, where such response is never 
achieved [4]. To undermine this difference, loss of re-
sponse is sometimes referred to as secondary nonre-
sponse. Based on the mechanisms involved, loss of re-
sponse can be either classified as immune-mediated (for-
mation of antibodies against anti-TNF) or nonimmune 
mediated (accelerated drug clearance due to burden of 
disease, weight or male gender, nonadherence, fibroste-
notic disease phenotype) [4]. Therapeutic drug monitor-
ing (TDM) and antidrug antibody measurement are in-
creasingly used in the setting of a loss of response and data 
supporting their application in daily practice are emerg-
ing [6–8]. However – despite acknowledging the useful-
ness of TDM – current guidelines of the European Crohn’s 
and Colitis Organisation (ECCO) lack of a clear recom-
mendation regarding optimal time-point, adequate 
thresholds, and TDM’s exact role in the long-term thera-
peutic algorithm [9, 10]. 
Therefore, we performed an expert panel discussion to 
reach a consensus statement based on the available litera-
ture about TDM. The goal of this discussion was to elab-
orate an algorithm for TDM in the context of biological 
therapy in IBD and a loss of response to such treatment. 
During an expert meeting, the relevance of thresholds 
and cutoff values for adequate drug concentrations and 
antidrug-antibody titers were discussed, and a therapeu-
tic decision pathway was elaborated. The discussion fo-
cused on TDM for loss of response only, so therapy mon-
itoring per se was not within the scope of the panel discus-
sion. With this consensus study, we sought to answer the 
following questions: (1) when and why to measure and 
how to interpret drug levels? (2) when and why to mea-
sure and how to interpret antidrug antibody titers? and 
finally, and (3) what is the best treatment algorithm in 
case of a loss of response to anti-TNF?
Literature Review
Definition of Loss of Response
There is no universally accepted definition of loss of 
response to anti-TNF treatment and hence its reported 
frequency is highly variable. Definitions used in clinical 
trials, observational studies, and reviews are (1) reemer-
gence of clinical symptoms after induction of response, 
verified by an increase in clinical activity scores such as 
the Crohn’s disease activity index (CDAI, e.g., 70 point 
change) or Mayo score (e.g., 3 point change) [11, 12]; (2) 
patient’s perspective of increasing symptoms [13]; and 
(3) need for dose intensification or treatment discontinu-
ation with a switch to other agents [5, 14, 15]. Current 
ECCO guidelines suggest the following 2 possible defini-
tions for loss of response in CD – acknowledging that no 
consensus exists: For CD (1) a CDAI > 150 with an in-
crease of > 70 points or (2) a CDAI increase of ≥100 points 
[9]; For UC, ECCO did not release a statement regarding 
the definition of loss of response [10]. However, a Mayo 
score of > 2 or an increase of 3 or more points might be 
used in daily clinical practice [16, 17].
Drug Levels and Loss of Response
Several studies demonstrated higher efficacy of anti-
TNFs with higher serum drug levels, both in UC and CD, 
as well as for infliximab and other anti-TNF agents. Most 
data derive from retrospective analyses of prospective tri-
als, which have been nicely summarized in a comprehen-
sive review by Sorrentino et al. [18] In CD, high or detect-
able infliximab trough levels were associated with higher 
rates of ongoing clinical response compared to low or un-
detectable levels. These rates were (1) 82 vs. 6% (for de-
tectable vs. nondetectable) [19]; (2) 74 vs. 59% (for cutoff 
> 3 μg/mL); [20] (3) 39 vs. 18% (for cutoff ≥3.5 μg/mL);[21] 
4) 92 vs. 14% (for cutoff > 0.3 μg/mL) [22]; and (5) 100 vs. 
80% (for cutoff > 5 μg/mL) [22]. Moreover, there was a 
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drug concentrations above 3 μg/mL [23]. Clinical remis-
sion rates increased after dose escalation to reach target 
levels of 3–7 μg/mL (from 65 to 88%) [24]. There was a 
longer duration of clinical response in patients with a 
threshold of > 12 μg/mL [25]. In addition, higher rates of 
endoscopic remission (47 vs. 19%) were observed with 
detectable infliximab levels (vs. nondetectable) [19]. In 
UC, detectable infliximab levels were also associated with 
higher clinical (69 vs. 15%) and endoscopic (76 vs. 28%) 
response rates [26]. Patients in endoscopic remission had 
higher levels of infliximab (8.1 vs. 2.9) and an infliximab 
threshold level of > 6.6 μg/mL predicted endoscopic re-
sponse with an OR of 18.1 [27]. In both UC and CD, loss 
of response to infliximab was attributed to low drug levels 
in 45% [28].
Fewer studies have been performed with adalimumab. 
In CD, trough levels of ≥5 μg/mL have been identified as 
predictive for treatment continuity with an OR of 4.5 
[29]. Higher trough levels were further observed with 
clinical remission and mucosal healing [30]. In UC, pa-
tients with histological and endoscopic inflammation had 
lower drug levels, while those in clinical remission and 
with mucosal healing showed higher serum concentra-
tions of adalimumab [31]. A comprehensive analysis of 
145 patients examined the impact of adalimumab and in-
fliximab drug levels in both UC and CD [32]. The follow-
ing rates of mucosal healing were found: (1) with inflix-
imab 50% for > 4 μg/mL, 85% for > 6 μg/mL, and 90% for 
> 8 μg/mL and (2) with adalimumab 50% for > 7.5 μg/mL, 
75% for > 8 μg/mL, and 90% for > 12 μg/mL [32]. A plateau 
was reached with > 12 μg/mL (adalimumab) and > 8 μg/
mL (infliximab). For certolizumab, even fewer data are 
available: with higher drug levels (≥23.30 vs. < 8.98 μg/
mL), more CD patients were found to be in clinical remis-
sion (93 vs. 50%), endoscopic remission (75 vs. 30%), and 
to show endoscopic response (87.5 vs. 20%) [33]. 
Despite these positive data – however – in some trials, 
no association between drug levels and treatment out-
come was seen: in the SONIC trial, no significant differ-
ences were observed in terms of remission rates at week 
50 when patients with nondetectable infliximab levels 
(0 μg/mL) were compared with patients with higher drug 
levels (> 6 μg/mL, 67 vs. 87%) [18, 20]. Similar findings 
were reported by Pariente et al. [34] In addition, optimal 
cutoff values remain unclear. This is mainly attributed to 
the fact that many different thresholds have been used in 
the so far conducted trials, ranging from > 1 to > 12 μg/mL 
in case of infliximab. Different outcomes were used to 
define therapeutic response ranging from clinical re-
sponse, remission to endoscopic response, and remission. 
Since most data evolve from retrospective analyses of 
prospective studies, the evidence for TDM is low. The val-
ue of proactive drug level measurements and targeting 
infliximab treatment to a predefined serum concentra-
tion (target: 3–7 μg/mL) were evaluated in the TAXIT 
trial: While indeed clinical remission rates increased with 
dose escalation in patients with subtherapeutic drug lev-
els, this strategy was not superior to clinically based dos-
ing [24]. Similarly, maintaining infliximab above 3 μg/mL 
did not result in higher rates of steroid-free clinical remis-
sion than adapting dose based only on symptoms (TAI-
LORIX trial) [35]. Taken together, no clear recommenda-
tions for the use of TDM and for optimal thresholds in 
particular exist [7]. Suggested cutoffs vary from > 2 to 
5–10 μg/mL. Current recommendations regarding the 
use of TDM and adequate threshold levels in IBD patients 
are summarized in Table 1 [9, 10, 36–40].
Antidrug Antibodies
Development of antidrug antibodies, a process called 
anti-TNF immunogenicity, may also affect the efficacy of 
anti-TNF treatment. Antidrug antibody formation has 
been observed with all anti-TNF agents used in IBD. Of 
note, episodic dosing resulted in higher antibody titers 
than did scheduled dosing [25, 41–45]. Antidrug anti-
bodies have been linked to higher rates of loss of response 
and higher likelihood of transfusion reactions [25, 42, 
43]. Antidrug antibody titers can be measured with com-
mercially available tests, which are based on ELISA, RIA, 
or HMSA methods [6, 41, 46]. Data on the association 
between presence of antidrug antibodies and disease out-
come are inconsistent [41]. In CD studies with episodic 
dosing of infliximab, higher antibody titers were linked to 
shorter duration of response and lower response rates, 
while no such association was seen with scheduled dosing 
except for the SONIC trial, where some improvement was 
observed with inconclusive antidrug antibody titers [19, 
20, 25, 42–44]. In UC, even higher response rates were 
seen with detectable antibodies, which were probably 
confounded by higher trough levels in these patients [47]. 
No such association was found in the study by Seow et al. 
[26]. For adalimumab and certolizumab, no associations 
between antidrug antibodies and disease outcome were 
seen [14, 48, 49]. Detailed descriptions of these trials can 
be found in the thorough reviews by Scott and Lichten-
stein [41] and by Khanna et al. [6, 41]. No clear cutoffs for 
antidrug antibodies exist due to different measurement 
methods and the fact that antidrug antibodies may be 
only transient in a considerable proportion of patients. 









































































ies, others used defined threshold values. There are no 
clear recommendations regarding the use of antidrug an-
tibodies in IBD treatment. In addition, there is no con-
sensus regarding adequate threshold values (Table 1). 
However, antidrug antibody titers may have their value 
in clinical practice. A study from the Mayo Clinic re-
vealed higher response rates for switch of anti-TNF agent 
compared to dose intensification in case of presence of 
antidrug antibodies (92 vs. 17%), while dose intensifica-
tion was more effective if no antidrug antibodies were 
present (86 vs. 33% compared to switch of anti-TNF 
agent) [28]. Similarly, Roblin et al. [50] demonstrated 
high clinical response rates (67%) with adalimumab dose 
optimization in case of low trough levels and nondetect-
able antidrug antibodies. In addition, combined interval 
shortening and dose intensification appears to be particu-
larly effective for restoring therapeutic drug levels when 
antidrug antibodies titers are low [51]. Nonetheless, dose 
intensifications can still be effective even in case of high 
antidrug antibody titers (in 60% compared to 74% effi-




To establish a consensus on the use of TDM in the context of 
loss of response to anti-TNF treatment, we performed a vote 
among IBD experts using a Delphi-style process [52]. First, we 
conducted a literature review using PubMed and Embase. The fol-
lowing key search items were used: loss of response, TDM, anti-
TNF, antidrug antibodies, and IBD. In addition, guidelines from 5 
gastroenterology societies were consulted: American Gastroenter-
ology Association, American College of Gastroenterology, ECCO, 
Asian Pacific Association of Gastroenterology and World Gastro-
enterology Organisation. In a second step, 8 IBD specialists par-
ticipated in a 3-h meeting and rated different statements on an 
even Likert-scale ranging from 1 to 4, based on their expert opin-
ion and the available literature: 1 indicated strong disagreement 
with a specific statement, 2 disagreement, 3 agreement, and 4 in-
dicated strong agreement. The statements included (i) reason for 
and optimal time-point of TDM; (ii) use of antidrug antibodies; 
(iii) definition of loss of response; and (iv) most adequate treat-
ment strategies in case of loss of response to anti-TNF. A list of the 
statements used for the first round of voting can be found in online 
Supplementary Table 1 (for all online suppl. material, see www.
karger.com/doi/10.1159/000501930). Participants were blinded to 
the votes of the other IBD experts. The voting process was followed 
by a panel discussion to refine the statements. A statement was 
Table 1. Current recommendations regarding drug levels and antidrug antibodies in IBD 
ECCO AGA ACG WGO APAGE













any other anti-TNF. 
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loss of response and














No statement No statement
Use of antidrug
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any other anti-TNF. 
It can help determine
the cause of a secondary
loss of response and
may be adopted in dose 
reduction strategies
No statement
Cut-off values for 
antidrug antibodies
No statement No statement No statement No statement No statement
IBD, inflammatory bowel disease; ACG, American College of Gastroenterology; AGA, American Gastroenterology Association; APAGE, 
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considered accepted if the mean rating value was 3 or more. As 
data are limited for biologics beyond the anti-TNF mode of action, 
statements were restricted to anti-TNF treatment. The 8 IBD ex-
perts were as follows: 5 experts practice in and/or are affiliated with 
an academic institution (university hospital level), 2 experts prac-
tice in private practice, and 1 expert practices at a large commu-
nity hospital (all in Switzerland, Europe).
Ethical Statement
This study did not include patient subjects. Therefore, as for 
other Delphi-technique based consensus paper, ethical approval 
was not required [53].
Results
TDM for Anti-TNF
After the specialist panel opinion, the following con-
sensus on therapeutic drug levels was achieved: (1) loss of 
response is associated with low or undetectable serum 
drug concentration in 50–70% of cases (mean value 3.4, 
online Suppl. Fig. 1) and (2) both in CD and UC, loss of 
response is associated with low or undetectable serum 
drug levels (mean value 3.6, online Suppl. Fig. 1). There 
was a consensus on how anti-TNF clearance occurs: 
through immune-mediated reactions (with formation of 
antidrug antibodies, mean value 3.6) and nonimmune re-
actions (mean value 3.6, online Suppl. Fig. 1). There was 
strong agreement that nonimmune-mediated drug clear-
ance is affected by severity and extent of IBD (mean value 
3.9), male sex (mean value 3.3), BMI (mean value 3.5), 
and concomitant use of immunomodulators (mean value 
3.8, online Suppl. Fig. 2). There was also strong consensus 
on when to measure drug concentrations in terms of inf-
liximab (trough levels immediately before the adminis-
tration of the next dose, mean value 4). However, there 
was no consensus regarding when to measure drug con-
centrations of subcutaneously administered anti-TNF. In 
terms of adequate anti-TNF levels, there was strong 
agreement that mucosal healing should be the target to 
treat. Optimal cutoff values to achieve this goal were con-
troversially discussed (online Suppl. Fig.  3). However, 
there was a final agreement for infliximab (5 μg/mL), 
adalimumab (8 μg/mL), and certolizumab pegol (10 μg/
mL, Fig. 1). There was no agreement regarding an opti-
mal threshold for golimumab.
Antidrug Antibodies
In a next step, use of and cutoff values for antidrug an-
tibodies were rated and discussed. There was overall 
agreement that high antidrug antibody titers are predic-
tive for adverse events and loss of response, but that they 
do not predict mucosal healing, CRP levels, or calprotec-
tin levels (online Suppl. Fig. 4). There was consensus to 
use manufacturer’s cutoff values for anti-infliximab and 
adalimumab antibody titers. The test provider usually in-
dicates if levels are considered positive or negative. All 
positive levels are meaningful. In addition, there was an 
overall agreement that antidrug antibodies should be 
measured when drug levels are lowest to avoid the risk of 
complex formation. There was no consensus on specific 
cutoff values for certolizumab pegol and golimumab. The 
value of anti-vedolizumab antibodies remains unclear – 
and was not within the scope of the current consensus. 
Loss of Response to Anti-TNF
There was overall agreement on how to define loss of 
response. The following parameters should be consid-
ered: symptoms (mean value 3.4), drug levels (mean value 
3.1), antidrug antibodies (mean value 3.1), and imaging 
such as sonography (mean value 3.1), endoscopy (mean 
value of 3.5), and MRI (in case of Crohn’s disease, mean 
value 3.1, online Suppl. Fig. 5). A calprotectin level of > 50 
μg/g was not considered to affect clinical decision making 
(mean value 2.6). However, after discussing optimal cut-
off levels, there was a strong agreement that calprotectin 
levels of > 200 μg/g should be taken into account, when 
defining loss of response. 
Therapeutic Algorithm for Patients with Loss of 
Response to Anti-TNF
The following interventions were deemed appropriate 
in the context of loss of response: (1) shortening of dose in-
terval or dose intensification in case of subtherapeutic drug 
levels, and absent or low antidrug antibody titers; (2) switch 
to another anti-TNF (= switch in class) in case of subthera-
peutic drug levels, but presence of antidrug antibodies; and 
(3) switch to a non-anti-TNF biologic (= switch out of class) 
in case of therapeutic drug levels regardless of presence or 
absence of antidrug antibodies. In case of subtherapeutic 
drug levels, but absent or low antidrug antibody titers, 2 op-
tions were deemed appropriate: (1) increasing the dose 







Fig. 1. Thresholds for adequate drug levels according to anti-TNF 






























































































experts agreed on the following: (1) dose intensification 
should be strived for if the clinical effect after drug admin-
istration is slow and (2) shortening the interval should be 
favored if a patient still responds to a maintenance dose, but 
experiences deterioration of IBD symptoms prior to the 
next drug administration. Figure 2 shows a treatment algo-
rithm in case of loss of response to anti-TNF, which was 
elaborated during this expert panel discussion.
Discussion
TDM and measurement of antidrug antibodies are in-
creasingly used in the context of loss of response to anti-
TNF. As of yet, ECCO guidelines mention these novel 
tools but without clear recommendations about their use 
[9, 10]. We herein report on the results from a Delphi-
based consensus meeting among 8 IBD specialists. The 
final statements are summarized in Table 2. 
Our expert panel reached consensus that loss of re-
sponse to anti-TNF is associated with inadequate anti-
TNF drug levels in both CD and UC. Indeed, despite some 
negative data from the SONIC trial, most published analy-
ses showed that higher trough levels lead to better clinical 
and endoscopic outcomes [18, 20]. Most data are available 
for infliximab, but similar results have been reported for 
other anti-TNF agents. There was consensus that drug lev-
els should be measured, when concentration is lowest (= 
trough levels). However, optimal cutoff values were dis-
cussed controversially among the panel experts. Current 
data are limited by the fact that studies used many different 
thresholds to define adequate and nonadequate drug con-
Assess drug levels
and ADA if needed
 ADA every 6–12
 months
 Calprotectin every
 3–6 months  Switch out of class
 Add or change IS
























Confirm active IBD/rule out alternative causes











Fig. 2. Treatment algorithm in case of loss 
of response to anti-TNF. ADA, antidrug 
antibody; CS, corticosteroids; IBD, inflam-
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centrations. Nonetheless, a second voting round resulted 
in a consensus for infliximab (5 μg/mL), adalimumab 
(8 μg/mL), and certolizumab pegol (10 μg/mL). These cut-
offs should be seen as guiding values. Such guidance may 
help clinicians to decide whether or not a current anti-TNF 
therapy is underdosed. A limiting factor of the current rec-
ommendation is that it may take up to 2 weeks until anti-
TNF drug levels are available. Thus, an intervention is of-
ten needed and performed before the results are known. 
Point-of-care measures of anti-TNF may allow clinicians 
to take more advantage of TDM in the future. 
Available data for antidrug antibodies are less consis-
tent than they are for drug concentrations [41]. However, 
our expert panel reached consensus that antidrug anti-
body titers are useful and high titers are associated with 
loss of response to anti-TNF. This agreement was achieved 
based on (1) data from the SONIC trial [20], (2) a recent 
meta-analysis showing worse outcome with antidrug an-
tibodies at least in CD [54], (3) and the fact that – if anti-
drug antibodies are present – switch to another anti-TNF 
results in better clinical response than dose intensifica-
tion [28]. Thus, antidrug antibodies should be taken into 
consideration when it comes to define loss of response to 
anti-TNF. However, threshold values remain unknown. 
As of today, any positive result evolving from antibody 
testing (based on the manufacturer’s protocol) should be 
considered clinically meaningful. 
Based on these data and agreements, both trough levels 
and antidrug antibody titers should be seen as key deter-
minants in the treatment algorithm. After loss of response 
is confirmed, drug monitoring is recommended. If thera-
peutic drug levels are detected, anti-TNF dose intensifica-
tion has no benefit. Treatment should be switched out of 
class, high dose steroids might be started, or even surgery 
might be considered. In case of inadequate drug levels, 
antidrug antibody titers may help in clinical decision 
making: (1) undetectable antibody or low antibody titers 
justify dose intensification, while (2) high antidrug anti-
body titers should lead to a therapeutic switch out of class 
or maybe within class, but with optimization of concomi-
tant immunomodulation. Some anti-TNF has lower im-
munogenic potential than others (e.g., adalimumab) [55]. 
This strategy is mainly based on the retrospective analysis 
from Mayo Clinic, where in patients with low drug levels 
dose intensification was superior to anti-TNF switching, 
but in patients with antidrug antibodies, switching to oth-
er agents was superior to dose escalation [28]. In another 
study – however – dose intensification was effective even 
in patients with high antidrug antibody titers [34]. 
Our consensus recommendations have several limita-
tions. They only discuss anti-TNF treatment, since conclu-
sive data are still missing for the newer non-anti-TNF bio-
logics. Measuring vedolizumab levels is complicated be-
cause of saturation of the target receptor. In addition, 
patients may be in clinical remission despite undetectable 
or very low vedolizumab levels. Ustekinumab trough levels 
can now be measured. However, data supporting their use 
in clinical practice are too sparse [7]. The literature review 
was not conducted in the sense of a systematic review, but 
rather based on recent meta-analyses, reviews, guidelines, 
and studies in high impact journals. A further limitation of 
our consensus is that there is still no generally accepted 
definition for loss of response to anti-TNF. Therefore, the 
therapeutic algorithm provided in Figure 2 should be seen 
as guidance rather than a rule for every patient. Clinical 
decision making should be discussed on individual basis.
In conclusion, a Delphi-style consensus among 8 IBD 
experts shows that TDM and measurement of antidrug 
antibody titers are useful in the context of loss of response 
to anti-TNF. Optimal cutoff levels depend on the type of 
anti-TNF. These values are critical in the decision-mak-
ing process. More studies are needed to address the value 
of such measurements for non-anti-TNF biologics.
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Table 2. Overview of the final statements made during the expert 
panel discussion
Final statements
Loss of response is associated with inadequate drug levels in
both CD and UC
Best time-point for measuring drug levels is prior to the next
application (trough levels)
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